HGH FRAGMENT 176-191
Also known as
HGH FRAGMENT 176-191 is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health.
Evidence
Animal or in-vitro only
Risk band
Known AEs, monitoring advised
Research goals
Summary
HGH fragment 176-191 (AOD-9604) is a peptide fragment of human growth hormone developed for its metabolic, fat-loss-oriented properties, with an obesity program that had reached phase IIa trials by early 2002 [2]. It is also discussed among growth-hormone-axis peptides said to activate IGF-1 signaling and satellite-cell repair, though the orthopaedic review covering it emphasizes that current evidence is largely preclinical and there is a present lack of clinical trials [1]. A rabbit osteoarthritis study found intra-articular AOD-9604 injection reduced cartilage degeneration and shortened lameness, particularly when combined with hyaluronic acid [4]. The peptide is banned by the World Anti-Doping Agency and has been targeted by validated urine-detection methods for anti-doping purposes [3]. Overall the provided literature is thin and lacks completed, reported human efficacy trials, so therapeutic benefit in people remains unestablished.
Sources
- 1. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026.
- 2. AOD-9604 Metabolic Current opinion in investigational drugs (London, England : 2000), 2004.
- 3. Detection and in vitro metabolism of AOD9604 Drug testing and analysis, 2015.
- 4. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model Annals of clinical and laboratory science, 2015.
For educational purposes only.